Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment

Commentary
Video

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Coral Olazagasti, MD, assistant professor, Clinical Medical Oncology, Department of Medicine, Division of Medical Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®, and the importance of having conversations such as these.

During the event, Olazagasti presented a case study of a patient with non–small cell lung cancer (NSCLC) harboring an ALK alteration. The patient initially had an unconventional clinical presentation that appeared to be primary thyroid disease but was ultimately diagnosed as lung adenocarcinoma, she details. PET/CT scans revealed FDG avid lymph nodes in the neck, cheek and abdomen that signaled a potential malignancy, along with diffuse FDG uptake in the thyroid gland, peribronchial thickening. The patient's immunoprofile favored the lung as the origin of disease.

After undergoing next-generation sequencing, the patient was identified as harboring an ALK mutation and treated with 600 mg of alectinib (Alecensa) every 12 hours. The patient initially achieved a complete response on initial PET scan, but later began experiencing cervical lymph nodes. A follow-up scan demonstrated signs of disease recurrence, and the patient was switched to lorlatinib (Lorbrena). Carboplatin/pemetrexed was then added to this regimen, and improvements in response were observed. The patient is currently on maintenance pemetrexed and lorlatinib.

The presentation prompted a thorough discussion among colleagues, where varying perspectives were evaluated and different treatment options were explored, Olazagasti says. The interactive nature of the case presentation allowed for a collaborative exchange of ideas and insights from the audience, she adds. Colleagues provided valuable feedback and suggestions, including key considerations if the patient's disease transformed into a squamous cell presentation, and the importance of repeating biopsies or adjusting treatment accordingly, Olazagasti details.

The experience underscored the dynamic and nuanced nature of medicine, where clear guidelines may not always apply to atypical presentations, Olazagasti continues. Engaging in discussions with peers and considering alternative viewpoints ensures comprehensive patient care and enables clinicians to adapt their approach based on individual patient needs, she emphasizes.

Ultimately, the case presentation served as a reminder of the importance of interdisciplinary collaboration and ongoing learning in delivering optimal patient care, Olazagasti says. By continuously seeking feedback and staying informed about the latest studies and trials, clinicians can ensure that they are providing the best possible treatment options for their patients, Olazagasti concludes.

Related Videos
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center
Robert DeBernardo, MD, section head, Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic
Abhishek Tripathi, MD, genitourinary medical oncologist, City of Hope
Burton Eliot Appel, MD, Hackensack Meridian Health
Neal Shore, MD, FACS,